Initial Data Shows Promising Results for Non-Viral Gene Therapy for Noninfectious Uveitis
Eyevensys presented results from the first part of its Phase 1/2 study for noninfectious uveitis. The technology used includes a non-viral gene therapy ocular drug delivery platform that uses a two-part Electrotransfection System that delivers DNA plasmids encoding therapeutic proteins into the ciliary muscle. The eye is then turned into a biofactory and causes the ciliary muscle to produce the therapeutic protein that reaches the back of the eye. The first part of the study tested its lead product, EYS606, a non-viral vector encoding an anti-tumor necrosis factor (alphaTNFα) protein.
The trial included 9 patients (3 cohorts) with late-stage noninfectious uveitis treated with EYS606. Results showed that clinical improvements lasted 6 months after just one treatment for 3 patients. One patient in the lowest dose cohort experienced a >10 ETDRS letter improvement in best corrected visual acuity (BCVA), whereas two patients in the highest dose cohort experienced a significant reduction of macular edema via optical coherence tomography associated with at least +12 ETDRS letters increase in BCVA from baseline.
The Phase 2 clinical study targets patients with active chronic noninfectious uveitis. Eyevensys will also conduct additional testing of different proteins for other ophthalmic diseases, including retinitis pigmentosa, dry age-related macular degeneration (AMD), glaucoma, macular edema associated with wet-AMD, diabetic macular edema, and central retinal vein occlusion.
You can read more here.
